Nephros Launches New S100 In-Line Microfilter

NewMediaWire
04-28

New Filter Offers Enhanced Installation Flexibility for Bacterial Retention

SOUTH ORANGE, NJ - April 28, 2025 (NEWMEDIAWIRE) - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to medical and commercial markets, today announced the launch of its S100 In-Line filter.

The S100 In-Line filter model is an extension of the existing S100 microfiltration line, expanding Nephros' infection control portfolio to offer greater flexibility in installation and broader application versatility. Designed to support bacterial remediation in both clinical and non-clinical settings, the new in-line model enables installations beyond traditional sink and shower fixtures to include low-pressure plumbing environments commonly found in emergency eyewash and shower stations, pharmaceutical and laboratory settings, dental equipment, and recreational vehicle water supplies.

The new in-line model maintains the trusted performance and safety standards of the S100 product line, such as a 0.1-micron pore size and FDA 510(k)-clearance as a Class II medical device. It features an increased flow rate, a filter life of up to 90 days, and achieves bacterial retention performance in accordance with ASTM F838 standards. With this release, Nephros bridges the functional gap between its microfiltration and ultrafiltration product lines, offering a more complete and versatile product portfolio.

"The S100 in-line microfilter is a practical extension of our medical-grade filtration offerings," said Robert Banks, President & CEO of Nephros. "It allows us to address specific installation scenarios where traditional sink or shower fixture filters are not suitable, and within low-pressure environments where the use of our in-line ultrafilters is not appropriate. This addition enhances our ability to support customers with more tailored, flexible water safety solutions."

The S100 In-Line microfilter is available in two configurations, Quick Connect (70-0288) and Threaded (70-0289), to accommodate varying installation needs. Two compatible installation kits (70-0290 and 70-0347), ensure ease of integration across diverse environments.

About Nephros

Nephros is a leading provider of filtration products to the medical, commercial, and industrial markets, offering a wide range of solutions that deliver superior filtration performance. With its advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality.

For more information about Nephros and its support for water safety, visit nephros.com

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros' expected benefits of the S100 In-Line filter and other statements that are not historical facts, including statements that may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including inflationary factors and general economic conditions, changes in business and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers, distributors and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros' reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, which it may update in Part II, Item 1A Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

Investor Relations Contacts:

Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com

Robert Banks, CEO
Nephros, Inc.
(201) 343-5202
robert.banks@nephros.com

Judy Krandel, CFO
Nephros, Inc.
(201) 343-5202
judy.krandel@nephros.com

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10